Business News

Biogen Pays Ionis $45 Million to License its Investigational Alzheimer’s Disease Drug

CARLSBAD, Calif., Dec. 19, 2019 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production of microtubule-associated protein tau (MAPT), or tau, in the central nervous system. …

Read More »

Exelixis Partners with Roche for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ:EXEL) today announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX®), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ®), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. The clinical program, which will be co-funded by …

Read More »

Arcus and Genentech Enter Clinical Collaboration for Novel Combinations for Colorectal and Pancreatic Cancers

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company discovering and developing highly-differentiated therapies, today announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic …

Read More »

Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders

BOSTON & CAMBRIDGE, United Kingdom–(BUSINESS WIRE)–Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI …

Read More »

UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety

NEW YORK–(BUSINESS WIRE)–Accenture (NYSE:ACN) and UCB, a global biopharmaceutical company, have collaborated to build a safety solution based on Accenture’s INTIENT™ Pharmacovigilance to accelerate processing of individual patient safety case reports. This will help UCB uncover patient safety impacts from existing treatments and better manage the risks of new drugs and …

Read More »

Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement

SAN DIEGO & WATERTOWN, Mass.–(BUSINESS WIRE)–Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) and Tarveda Therapeutics, Inc. (“Tarveda”), a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger …

Read More »

Merck to Acquire ArQule for $2.7 Billion, Expanding its Oncology Pipeline

KENILWORTH, N.J. & BURLINGTON, Mass.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an …

Read More »

Diplomat and OptumRx Combine to Advance Access to Specialty Pharmacy Care and Infusion Services, Improve Health Outcomes

EDEN PRAIRIE, Minn. and FLINT, Mich.–(BUSINESS WIRE)–OptumRx, the pharmacy care services business of Optum, and Diplomat, a provider of specialty pharmacy and infusion services, are combining. The agreement calls for the acquisition of Diplomat’s outstanding common stock for $4.00 per share through a cash tender offer and assumption of outstanding …

Read More »

XBiotech Agrees to Sell Anti-IL-1⍺ Antibody Bermekimab to Janssen in $1.3 Billion Deal

HORSHAM, Pa., Dec. 7, 2019 /PRNewswire/ — Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development …

Read More »

AbbVie Collaborates with Scripps Research to Develop a Broad Range of New Therapeutics

NORTH CHICAGO, Ill. and LA JOLLA, Calif., Dec. 9, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic …

Read More »